A. Choi, Chadha Bhawneet, Hiten Doshi, Charly Edmiston, J. Elkon
{"title":"Temporal trend in the use of medical interpreters for gastric cancer patients: a single-institution study","authors":"A. Choi, Chadha Bhawneet, Hiten Doshi, Charly Edmiston, J. Elkon","doi":"10.53876/001c.73647","DOIUrl":"https://doi.org/10.53876/001c.73647","url":null,"abstract":"","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"48 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116363121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"What is a Global Cancer Moonshot? Evaluating Potential Impact and Gaps Generated by the US-Africa Leaders Summit Cancer Commitments Portfolio","authors":"M. Bhattacharya","doi":"10.53876/001c.73633","DOIUrl":"https://doi.org/10.53876/001c.73633","url":null,"abstract":"","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134531655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D. U. Portillo, Ana Maria Mendoza Sanchez, N. Quilantan, Marcela Mazo Canola, L. M. U. Portillo, J. Gelfond, J. Peguero
{"title":"Is physician-patient language concordance better for clinical trial enrollment in breast cancer patients","authors":"D. U. Portillo, Ana Maria Mendoza Sanchez, N. Quilantan, Marcela Mazo Canola, L. M. U. Portillo, J. Gelfond, J. Peguero","doi":"10.53876/001c.73762","DOIUrl":"https://doi.org/10.53876/001c.73762","url":null,"abstract":"","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"66 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133247327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Suman Gaire, P. Budhathoki, A. Shah, Ujjwal Karki, S. Yadav
{"title":"Racial disparities in response to neoadjuvant therapy among patients with triple-negative invasive ductal breast carcinoma","authors":"Suman Gaire, P. Budhathoki, A. Shah, Ujjwal Karki, S. Yadav","doi":"10.53876/001c.73726","DOIUrl":"https://doi.org/10.53876/001c.73726","url":null,"abstract":"","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114283418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Linnea Cripe, A. Moten, Ashley Hendrix, M. Fleming
{"title":"Understanding Improvements in Disparities in Breast Cancer Care in Memphis, Tennessee: A Comparison of Two Time Cohorts","authors":"Linnea Cripe, A. Moten, Ashley Hendrix, M. Fleming","doi":"10.53876/001c.73692","DOIUrl":"https://doi.org/10.53876/001c.73692","url":null,"abstract":"","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"49 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125238351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ana María Ávila, Eshana E. Shah, Jerry W Luo, Tasha Chasson, Elizabeth Raigoza, Ana Gordon, Michael Berbaum, A. Gallo, I. Khan
{"title":"A Mixed Methods Study to Examine the Influence of Structural Racism on Treatment in Aggressive Hematologic Malignancies","authors":"Ana María Ávila, Eshana E. Shah, Jerry W Luo, Tasha Chasson, Elizabeth Raigoza, Ana Gordon, Michael Berbaum, A. Gallo, I. Khan","doi":"10.53876/001c.73330","DOIUrl":"https://doi.org/10.53876/001c.73330","url":null,"abstract":"","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"42 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131210955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Medicaid Expansion and Access to Surgical Treatment Among Patients with Non Small Cell Lung Cancer","authors":"Vijai Krishnan, C. Seder, Yanyu Zhang, G. Alex","doi":"10.53876/001c.73737","DOIUrl":"https://doi.org/10.53876/001c.73737","url":null,"abstract":"","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"244 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127241903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Response to COVID-19 Vaccination in Adults with Hematologic Malignancies Compared to Patients with HIV and Solid Tumors: Observations from A Single Tertiary Institution","authors":"Bowen He, P. Vishnu, H. DeBerg, D. Aboulafia","doi":"10.53876/001c.73728","DOIUrl":"https://doi.org/10.53876/001c.73728","url":null,"abstract":"","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115572098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The treatment metastatic non-small cell lung cancer (NSCLC) is largely influenced by the incorporation of immune checkpoint inhibitors (ICI) in the frontline setting. There are several ICI approved for the management of NSCLC based on the PD-L1 expression of the tumors. PD-L1 is a controversial biomarker with various inconsistencies in expression owing to temporal and spatial heterogeneity. Tumor mutational burden is another much studied biomarker associated with its own challenges and questionable concordance with tumor PD-L1 expression. In this article, we aim to discuss the challenges associated with the existing biomarkers, highlighting the need for emerging biomarkers that can help with decision making in the management of this there where several therapeutic options exist. There are emerging “me too” PD-1/PD-L1 drugs which may serve its purpose in many counties where there is limited access to current approved ICIs. What is increasingly apparent is the need to move the needle forward in the treatment of NSCLC and we will discuss the challenges associated with the current therapeutic landscape and the emerging checkpoints and the future directions that are being explored in the management of metastatic NSCLC.
{"title":"Immune checkpoint inhibitors in metastatic NSCLC: challenges and future directions","authors":"A. Sridhar, P. Singh, K. Parikh","doi":"10.53876/001c.72631","DOIUrl":"https://doi.org/10.53876/001c.72631","url":null,"abstract":"The treatment metastatic non-small cell lung cancer (NSCLC) is largely influenced by the incorporation of immune checkpoint inhibitors (ICI) in the frontline setting. There are several ICI approved for the management of NSCLC based on the PD-L1 expression of the tumors. PD-L1 is a controversial biomarker with various inconsistencies in expression owing to temporal and spatial heterogeneity. Tumor mutational burden is another much studied biomarker associated with its own challenges and questionable concordance with tumor PD-L1 expression. In this article, we aim to discuss the challenges associated with the existing biomarkers, highlighting the need for emerging biomarkers that can help with decision making in the management of this there where several therapeutic options exist. There are emerging “me too” PD-1/PD-L1 drugs which may serve its purpose in many counties where there is limited access to current approved ICIs. What is increasingly apparent is the need to move the needle forward in the treatment of NSCLC and we will discuss the challenges associated with the current therapeutic landscape and the emerging checkpoints and the future directions that are being explored in the management of metastatic NSCLC.","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"35 28","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"113971136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lung cancer is the second-most prevalent cancer and, the most common cause of cancer-related mortality throughout the world. Evidence-based strategies to decrease its incidence and mortality are being implemented in different parts of the world. Smoking cessation policies are being actively publicized to decrease the incidence of tobacco related cancers including lung cancer. Screening program for early detection of localized lung cancer which can then be targeted by a multimodality approach utilizing surgery, radiation, chemoimmunotherapy to achieve cure is now becoming the standard in several high-income countries. Precision medicine in lung cancer is booming with metastatic non-curative cancers targeted with small molecule tyrosine kinase inhibitors. However, these advancements are not available all around the world. Inequalities exist in the management of lung cancer, mostly driven by the economic differences between the countries. Raising awareness to these international barriers is pivotal for improving lung cancer related incidence and mortality.
{"title":"Lung cancer management in low and middle-income countries - current challenges and potential solutions","authors":"D. Uprety, Malini Surapaneni","doi":"10.53876/001c.73042","DOIUrl":"https://doi.org/10.53876/001c.73042","url":null,"abstract":"Lung cancer is the second-most prevalent cancer and, the most common cause of cancer-related mortality throughout the world. Evidence-based strategies to decrease its incidence and mortality are being implemented in different parts of the world. Smoking cessation policies are being actively publicized to decrease the incidence of tobacco related cancers including lung cancer. Screening program for early detection of localized lung cancer which can then be targeted by a multimodality approach utilizing surgery, radiation, chemoimmunotherapy to achieve cure is now becoming the standard in several high-income countries. Precision medicine in lung cancer is booming with metastatic non-curative cancers targeted with small molecule tyrosine kinase inhibitors. However, these advancements are not available all around the world. Inequalities exist in the management of lung cancer, mostly driven by the economic differences between the countries. Raising awareness to these international barriers is pivotal for improving lung cancer related incidence and mortality.","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130614063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：